ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with

Authors: Antonio Llombart-Cussac, Jose Manuel Perez-Garcia, Elena Lopez-Miranda, Rui Rui Zhang Xiang, Miguel Sampayo-Cordero, Juliana Carvalho Santos, Olga Boix, Marta Beltran, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne-Claire Hardy-Bessard, Anna Compagnoni, Kathy Puyana Theall, Thomas Buechele, Tomer Wasserman, Javier Cortes

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1129

Source: Full article

---

Abstract

TPS1129